These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36402243)

  • 1. Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.
    Dogra S; Putnam J; Conn PJ
    Pharmacol Biochem Behav; 2022 Nov; 221():173493. PubMed ID: 36402243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
    Dogra S; Conn PJ
    Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in translating mGlu
    Tyler RE; Besheer J; Joffe ME
    Pharmacol Biochem Behav; 2022 Sep; 219():173450. PubMed ID: 35988792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.
    Di Menna L; Joffe ME; Iacovelli L; Orlando R; Lindsley CW; Mairesse J; Gressèns P; Cannella M; Caraci F; Copani A; Bruno V; Battaglia G; Conn PJ; Nicoletti F
    Neuropharmacology; 2018 Jan; 128():301-313. PubMed ID: 29079293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mGlu
    Joffe ME; Santiago CI; Oliver KH; Maksymetz J; Harris NA; Engers JL; Lindsley CW; Winder DG; Conn PJ
    Neuron; 2020 Jan; 105(1):46-59.e3. PubMed ID: 31735403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating mGlu
    Dogra S; Stansley BJ; Xiang Z; Qian W; Gogliotti RG; Nicoletti F; Lindsley CW; Niswender CM; Joffe ME; Conn PJ
    Biol Psychiatry; 2021 Sep; 90(6):385-398. PubMed ID: 33965197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
    Stansley BJ; Conn PJ
    Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu
    Joffe ME; Santiago CI; Vermudez SAD; Fisher NM; Dogra S; Niswender CM; Jeffrey Conn P
    Neuropsychopharmacology; 2021 Nov; 46(12):2148-2157. PubMed ID: 34035469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental expression of mGlu2 and mGlu3 in the mouse brain.
    McOmish CE; Demireva EY; Gingrich JA
    Gene Expr Patterns; 2016 Nov; 22(2):46-53. PubMed ID: 27818290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 - present).
    Qunies AM; Emmitte KA
    Expert Opin Ther Pat; 2021 Aug; 31(8):687-708. PubMed ID: 33719801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
    Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
    Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding.
    García-Bea A; Bermudez I; Harrison PJ; Lane TA
    J Psychopharmacol; 2017 Dec; 31(12):1519-1526. PubMed ID: 28655286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.
    Walker AG; Wenthur CJ; Xiang Z; Rook JM; Emmitte KA; Niswender CM; Lindsley CW; Conn PJ
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1196-201. PubMed ID: 25583490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms underlying prelimbic prefrontal cortex mGlu
    Joffe ME; Santiago CI; Stansley BJ; Maksymetz J; Gogliotti RG; Engers JL; Nicoletti F; Lindsley CW; Conn PJ
    Neuropharmacology; 2019 Jan; 144():19-28. PubMed ID: 30326237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.
    García-Bea A; Walker MA; Hyde TM; Kleinman JE; Harrison PJ; Lane TA
    Schizophr Res; 2016 Nov; 177(1-3):18-27. PubMed ID: 27130562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.
    Wierońska JM; Pilc A
    Neurochem Int; 2009; 55(1-3):85-97. PubMed ID: 19428811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.